Psychedelic drug developers rise after Trump signals regulatory support

COMPASS Pathways

20/04/2026 18:02

Updates

** Shares of psychedelic drug developers rise after U.S. President Donald Trump signed an executive order on Saturday, telling health regulators to speed up review of psychedelic drugs such as ibogaine and set aside $50 million for research

** Shares of AtaiBeckley ATAI.O jump 26.18%, Definium Therapeutics DFTX.O marginally up, Compass Pathways CMPS.O climb 48.20%, GH Research GHRS.O gain 14.04%, Enveric ENVB.O jump 138.48%

** U.S.-listed shares of Cybin HELP.O up 2.55%

** Brokerage Jefferies says the order is an "official stamp of validation to the class", showing government support is "real/actionable (not rhetorical)"

** Ibogaine is a naturally occurring psychoactive compound derived from an African shrub that is being studied as a potential treatment for addiction and mental health disorders

** Psychedelic drugs with Breakthrough Therapy Designation may get Commissioner National Priority Review Vouchers, cutting FDA review from 6-10 month review time down to 1-2 months, Jefferies noted

 (Reporting by Kamal Choudhury and Kunal Das in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))